Bogart Wealth LLC lower its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 2.2% through the third quarter, in accordance with the corporate in its most up-to-date disclosure with the Securities & Trade Fee. The agency owned 3,720 shares of the corporate’s inventory after promoting 85 shares through the interval. Bogart Wealth LLC’s holdings in AbbVie had been price $735,000 on the finish of the latest reporting interval.
Different giant buyers additionally just lately modified their holdings of the corporate. Fairway Wealth LLC bought a brand new place in shares of AbbVie through the 2nd quarter valued at $26,000. Ridgewood Investments LLC bought a brand new place in shares of AbbVie within the 2nd quarter price about $27,000. Quest Companions LLC elevated its place in shares of AbbVie by 4,140.0% through the 2nd quarter. Quest Companions LLC now owns 212 shares of the corporate’s inventory valued at $36,000 after buying an extra 207 shares over the past quarter. Redmont Wealth Advisors LLC bought a brand new place in shares of AbbVie through the 1st quarter valued at about $37,000. Lastly, Marquette Asset Administration LLC purchased a brand new stake in AbbVie within the third quarter price roughly $39,000. 70.23% of the inventory is at present owned by institutional buyers.
Insider Exercise
In different AbbVie information, Chairman Richard A. Gonzalez bought 66,500 shares of the inventory in a transaction on Monday, August fifth. The inventory was bought at a median worth of $186.52, for a complete worth of $12,403,580.00. Following the completion of the transaction, the chairman now owns 446,599 shares within the firm, valued at roughly $83,299,645.48. This represents a 0.00 % lower of their possession of the inventory. The transaction was disclosed in a doc filed with the Securities & Trade Fee, which could be accessed via this hyperlink. 0.25% of the inventory is at present owned by firm insiders.
Analyst Upgrades and Downgrades
Various analysis analysts have commented on the inventory. Morgan Stanley elevated their worth goal on shares of AbbVie from $211.00 to $218.00 and gave the corporate an “chubby” score in a analysis report on Monday, August twelfth. Piper Sandler lifted their goal worth on shares of AbbVie from $196.00 to $209.00 and gave the inventory an “chubby” score in a analysis report on Friday, August twenty third. Financial institution of America upped their worth goal on shares of AbbVie from $185.00 to $195.00 and gave the corporate a “impartial” score in a analysis report on Friday, October 18th. BMO Capital Markets lifted their worth goal on AbbVie from $214.00 to $220.00 and gave the inventory an “outperform” score in a report on Thursday, October seventeenth. Lastly, Cantor Fitzgerald restated an “chubby” score and set a $200.00 goal worth on shares of AbbVie in a report on Monday, August fifth. 4 analysis analysts have rated the inventory with a maintain score, 13 have given a purchase score and one has issued a powerful purchase score to the inventory. Based mostly on knowledge from MarketBeat.com, the inventory presently has a median score of “Reasonable Purchase” and a consensus worth goal of $198.47.
Get Our Newest Inventory Report on AbbVie
AbbVie Inventory Up 1.0 %
Shares of NYSE ABBV opened at $189.68 on Friday. The agency has a fifty day easy transferring common of $194.22 and a two-hundred day easy transferring common of $178.08. AbbVie Inc. has a 12 month low of $135.85 and a 12 month excessive of $199.95. The corporate has a present ratio of 0.81, a fast ratio of 0.71 and a debt-to-equity ratio of 8.51. The agency has a market capitalization of $334.95 billion, a PE ratio of 56.28, a price-to-earnings-growth ratio of two.66 and a beta of 0.63.
AbbVie (NYSE:ABBV – Get Free Report) final launched its quarterly earnings outcomes on Thursday, July twenty fifth. The corporate reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.08. The corporate had income of $14.46 billion through the quarter, in comparison with the consensus estimate of $14.02 billion. AbbVie had a internet margin of 9.71% and a return on fairness of 203.66%. AbbVie’s income was up 4.3% on a year-over-year foundation. Throughout the identical interval within the prior 12 months, the agency earned $2.91 earnings per share. Equities analysts count on that AbbVie Inc. will put up 10.85 earnings per share for the present 12 months.
AbbVie Proclaims Dividend
The corporate additionally just lately introduced a quarterly dividend, which can be paid on Friday, November fifteenth. Stockholders of file on Tuesday, October fifteenth can be given a $1.55 dividend. This represents a $6.20 annualized dividend and a dividend yield of three.27%. The ex-dividend date is Tuesday, October fifteenth. AbbVie’s dividend payout ratio is at present 183.98%.
AbbVie Firm Profile
AbbVie Inc discovers, develops, manufactures, and sells prescription drugs worldwide. The corporate gives Humira, an injection for autoimmune and intestinal Behçet’s ailments, and pyoderma gangrenosum; Skyrizi to deal with average to extreme plaque psoriasis, psoriatic illness, and Crohn’s illness; Rinvoq to deal with rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn’s illness; Imbruvica for the remedy of grownup sufferers with blood cancers; Epkinly to deal with lymphoma; Elahere to deal with most cancers; and Venclexta/Venclyxto to deal with blood cancers.
Additional Studying
Obtain Information & Rankings for AbbVie Each day – Enter your electronic mail deal with under to obtain a concise each day abstract of the newest information and analysts’ rankings for AbbVie and associated firms with MarketBeat.com’s FREE each day electronic mail publication.
